PURPOSE: A bisphosphonate compound is provided to suppress bond of PTP-1B(Protein Tyrosine Phosphate 1B) and IR(Insulin Receptor), to treat insulin secretion in pancreatic islet, and to be used as a preventive and therapeutic agent for type 2 diabetes.CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains zoledronate or a pharmaceutically acceptable salt thereof as an active ingredient. The diabetes is type 2 diabetes. Zoledronate or a pharmaceutically acceptable salt is administered to an individual in an amount of 0.001-0.2 mg/day, 0.15 mg/day, or 0.1 mg/day to prevent or treat diabetes. Zoledronate or a pharmaceutically acceptable salt is used by oral, intravenous, subcutaneous, and intrarectal administration. Zoledronate or a pharmaceutically acceptable salt suppresses bond of PTP-1B with IR.COPYRIGHT KIPO 2013[Reference numerals] (AA,FF) Insulin acceptor (BB) Non-activated type (CC) Insulin (DD) Pancreas (EE) Activated type (GG) Substrate phosphorylation (HH) Sugar absorption본 발명은 비스포스포네이트 또는 이의 약학적으로 허용되는 염을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물에 관한 것으로서 보다 구체적으로는 비스포스포네이트 화합물 중 특히 졸레드로네이트 또는 이의 약학적으로 허용되는 염을 유효성분으로 함유하는, 당뇨병, 보다 구체적으로 제2형 당뇨병의 예방 또는 치료용 약학적 조성물에 관한 것이다.
